Compare Novavax Inc (NVAX) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs TJX Companies Inc — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while TJX Companies Inc trades at $138.76 (market cap $152.62B). The key difference: TJX Companies Inc is far larger — about 83.9× Novavax Inc's market cap, and TJX Companies Inc pays a 1.38% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and TJX Companies Inc for 97 Days on average.
| NVAX | TJX | |
|---|---|---|
Market Cap | $1.82B | $152.62B |
Volume | 6,198,505 | 8,079,794 |
Sector | Health | Consumer Cyclical |
52-Week High | $12.75 | $168.41 |
52-Week Low | $6.22 | $122.84 |
Typical Hold Time | 59 Days | 97 Days |
Enterprise Value | $1.39B | $160.93B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
TJX trades at $138.75, down 0.04% on the day, with strong fundamental performance including 62.17% ROE and consistent earnings beats. The stock shows bullish technical momentum with support at $136 and resistance at $140. Revenue grew to $56.36B in 2025 with net income reaching $4.86B, while analyst consensus remains overwhelmingly positive with 85% buy ratings.
TJX presents a compelling investment case with projected 28% upside to the $174.15 consensus target, supported by expanding profit margins and robust cash flow generation. Key risks include competitive pressures in off-price retail and potential consumer spending volatility. The company's strong balance sheet and consistent dividend payments provide stability amid market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
